Bio Rad Labs Cl B (BIO.B) 141.98 $BIO.B Bio-Rad to

New Post Public Reply Private Reply Replies (0) Message Board

Jul 13, 2016 at 8:20 PM

Bio Rad Labs Cl B (BIO. 141.98 $BIO.B

Bio-Rad to Report Second-Quarter 2016 Financial Results Wednesday, August 3, 2016
Marketwire Canada - Mon Jul 11, 1:03PM CDT
HERCULES, CA--(Marketwired - Jul 11, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, will report financial results for the second quarter 2016 on Wednesday, August 3, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Daylight Time (5 PM Eastern Daylight Time) that day.
BIO: 144.21 (-0.69), BIO.B: 141.98 (unch)

Bio-Rad Unveils Amplichek II Quality Control, the First in a Series of Controls for the Molecular Diagnostics Testing Market
Marketwired - Mon May 23, 7:30AM CDT
HERCULES, CA--(Marketwired - May 23, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced its entry into the rapidly growing molecular diagnostics testing market with the launch of Amplichek™ II quality control, which was recently issued a de novo clearance from the U.S. Food and Drug Administration (FDA).
BIO: 144.21 (-0.69), BIO.B: 141.98 (unch)

Bio-Rad posts 1Q profit
Automated Insights - Thu May 05, 4:12PM CDT
HERCULES, Calif. (AP) _ Bio-Rad Laboratories Inc. (BIO. on Thursday reported first-quarter profit of $12.3 million.
BIO: 144.21 (-0.69), BIO.B: 141.98 (unch)

Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent
Marketwire Canada - Thu May 05, 3:16PM CDT
HERCULES, CA--(Marketwired - May 5, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2016.
BIO: 144.21 (-0.69), ILMN: 145.86 (-3.13), BIO.B: 141.98 (unch)

Bio-Rad Expands Its Cell Biology Portfolio With High Performance Flow Cytometer
Marketwired - Mon Feb 08, 3:30PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. and Propel Labs today announced that Bio-Rad has acquired a high performance analytical flow cytometer platform from Propel Labs that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. Bio-Rad expects to launch the instrument later this year.
BIO: 144.21 (-0.69), BIO.B: 141.98 (unch)

Bio-Rad to Report Fourth-Quarter and Full-Year 2015 Financial Results Thursday, February 25, 2016
Marketwired - Tue Feb 02, 2:36PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, will report financial results fourth quarter and full year 2015 on Thursday, February 25, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
BIO: 144.21 (-0.69), BIO.B: 141.98 (unch)

Bio-Rad Joins Food Safety Consortium With IBM and Mars, Incorporated
Marketwired - Tue Jan 12, 8:30AM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that it has joined the Consortium for Sequencing the Food Supply Chain established in 2015 by scientists from IBM Research (NYSE: IBM) and Mars, Incorporated. The consortium is combining advanced genomics with new informatics tools to observe microbial communities in food and detect hazards in the food supply chain that can threaten safety.
IBM: 158.02 (+0.98), BIO: 144.21 (-0.69), BIO.B: 141.98 (unch)

Bio-Rad Named One of the 2015 Top 100 Bay Area Innovators by Thomson Reuters
Marketwired - Tue Jan 05, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that it was named one of the "Thomson Reuters 2015 Top 100 Bay Area Innovators."
BIO: 144.21 (-0.69), BIO.B: 141.98 (unch)

Bio-Rad's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets
Marketwired - Mon Dec 21, 3:21PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance to market its TANGO infinity(R) system in the U.S. The system automates routine blood typing and screening testing procedures for patients and donors.
BIO: 144.21 (-0.69), BIO.B: 141.98 (unch)

Bio-Rad Receives FDA Clearance for Its D-100 System for A1c Testing
Marketwired - Wed Dec 16, 5:19PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that its D-100(TM) System for A1c testing has obtained clearance from the U.S. Food and Drug Administration to monitor the long-term blood glucose control of individuals with diabetes, as an aid in the diagnosis of diabetes, and to help identify those who may be at risk for developing the disease.
BIO: 144.21 (-0.69), BIO.B: 141.98 (unch)

Bio-Rad Reports Third-Quarter 2015 Financial Results
Marketwired - Tue Nov 03, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2015.
BIO: 144.21 (-0.69), BIO.B: 141.98 (unch)

Bio-Rad to Report Third-Quarter 2015 Financial Results Tuesday, November 3, 2015
Marketwired - Mon Oct 19, 3:15PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, will report financial results for the third quarter 2015 on Tuesday, November 3, 2015, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
BIO: 144.21 (-0.69), BIO.B: 141.98 (unch)

Bio-Rad Introduces the IH-500, a Fully Automated Random Access System for Blood Typing and Screening
Marketwired - Mon Aug 03, 7:30AM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., today announced the launch of the IH-500, a fully automated random access system for blood typing and screening, providing small and medium-size transfusion medicine laboratories fast and reliable results in a 24/7 environment. The IH-500 system is available in Europe, Asia, Africa, Australia, and Latin America.
BIO: 144.21 (-0.69), BIO.B: 141.98 (unch)

Bio-Rad Announces U.S. FDA Pre-Market Approval for the BioPlex 2200 HIV Ag-Ab Assay, a Novel Next Generation HIV Diagnostic Test
Marketwired - Tue Jul 28, 3:15PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration pre-market approval to offer its BioPlex(R) 2200 HIV Ag-Ab assay, the company's 5th generation HIV diagnostic test.
BIO: 144.21 (-0.69), BIO.B: 141.98 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...